GSK2849330

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline

Conditions

CancerNeoplasmsgastric/gastroesophageal cancer head and neck cancer or NSCLC stage III-IV melanoma

Phase 1

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors

CompletedNCT01966445

GlaxoSmithKlineCancer, Neoplasms

Start: 2013-11-26End: 2017-09-18Updated: 2019-07-01

Immuno Positron Emission Tomography Study of GSK2849330 in Subjects With Human Epidermal Growth Factor Receptor 3-Positive Solid Tumors

CompletedNCT02345174

GlaxoSmithKlineCancer, Neoplasms

Start: 2015-03-19End: 2016-06-02Updated: 2019-02-21

Phase 2

A phase I, first time in human, open-label, dose escalation study to investigate the safety, pharmacokinetics, and pharmacodynamics of anti-HER3 monoclonal antibody GSK2849330 in subjects with advanced HER3-positive solid tumors

Active, not recruitingNL-OMON44080

GlaxoSmithKlinegastric/gastroesophageal cancer head and neck cancer or NSCLC stage III-IV melanoma

Start: 2015-06-09Target: 40Updated: 2024-02-28

Related Papers

Response to ERBB3-Directed Targeted Therapy in <i>NRG1</i> -Rearranged Cancers

Cancer Discovery2018-04-02198 citations